The US Food and Drug Administration has cleared Medtronic's Hugo robotic-assisted surgery system for general surgery, Medtronic announced this week, The Robot Report writes. The clearance takes in all upper abdominal general surgical procedures, such as cholecystectomy, Roux-en-Y gastric bypass and ventral hernia repair, along with small bowel resection. On the lower abdomen, Hugo is cleared for inguinal hernia repair and appendectomy. Medtronic says these procedures account for about 3.5 million surgeries a year in the US.

Rajit Kamal, Medtronic's general manager of robotic surgical technologies, told The Robot Report that the company began its US rollout of Hugo in February last year and is in many leading hospitals with its urology indication. The FDA approved Hugo for urology in December 2025.

Kamal said Medtronic took two routes to the clearance: a US clinical trial run under an investigational device exemption, and data from outside the US. Hugo received CE marking for general surgery in Europe in 2022, and general surgery is its fastest-growing procedure mix outside the US, he said. Medtronic says Hugo is on track to pass 50,000 procedures worldwide by the end of its fiscal year.

Medtronic is also running a US study of Hugo in gynaecology. In September it invested $700 million in Cornerstone Robotics, which gave it rights to distribute that company's Sentire surgical system in some markets outside the US. The report does not give Hugo's price or say how many US hospitals will add the general surgery indication.

Source: The Robot Report

Background

Food and Drug Administration

Regulator

The United States federal agency that regulates food, drugs and medical devices.

Hugo

Surgical robot

Robotic-assisted surgery system from Medtronic with modular robotic arms and an open surgeon console.

Medtronic

Medical device company

Medical device company with its legal headquarters in Ireland and operational headquarters in the United States.